Skip to main content
iABC_Logo_153W_100H

Inhaled Antibiotics in Bronchiectasis and Cystic Fibrosis (iABC)

Inhaled Antibiotics in Bronchiectasis and Cystic Fibrosis (iABC)

Respiratory infections, frequently caused by drug-resistant bacteria, are the main cause of disease and death in people with cystic fibrosis (CF) and bronchiectasis (BE). Thanks to inhaled antibiotics, patients now live longer than ever before and enjoy a better quality of life. However, infections are increasingly becoming resistant to the few drugs available, putting patients’ lives at risk.

The iABC project is advancing the development of two inhaled antibiotics for patients with CF and BE. It is also working to identify ways of improving clinical trials of treatments for these serious diseases.

About Us

What is the iABC project?

About the Project

Clinical trials

What is the progress so far

Clinical Trials

Library

View our dissemination activities

Library

Video stories

Hear directly from those involved

Video Stories

Events

What related events are coming up

Events

EMBARC registry

Patients with non-CF bronchiectasis

EMBARC Registry